In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Autoimmune Diseases and Treatment

Edited by Edited by Yehuda Shoenfeld (Sheba Medical Center, Tel Hashomer, Israel) and M. Eric Gershwin (University of California, Davis, California)
Autoimmune Diseases and Treatment

Published: August 2005

Volume 1051

Learn More

Only in very recent times have therapies been developed that are specific to a particular manifestation of autoimmune disease, and these have begun to replace the all-purpose remedies of the past 30 years. This volume, which draws on the principles of immunology presented in Volume 1050, extends these concepts to the realm of clinical findings and current therapy for many autoimmune and connective tissue disorders. Both organ-specific and organ-nonspecific diseases are covered, and one section is entirely focused on treatment. Treatments using cytokines, chemokines, cognate receptors, and genetic interactions are particularly prominent in these reports, and attention is also paid to the increasing use of intravenous imunoglobulins and both monoclonal and imunosuppressive agents. A therapeutic void remains, but the work reported on here contributes considerably to the effort to fill that void.